Regeneration Technologies:
A Frontier in Cellular and Bioprinting Medicine.

We are building a clinically integrated platform that combines
cell therapy, tissue engineering, and next-gen bioprinting
to enable transformative therapies in regeneration medicine.
Learn more
About us.
We are a pioneering biomedical company advancing the future of regenerative medicine. With a robust intellectual property portfolio, validated preclinical outcomes, and a team of leading experts in the field, we are developing a clinically integrated platform at the intersection of cell therapy, tissue engineering, and next-generation bioprinting.

Our patented technologies open new possibilities in musculoskeletal repair, neuroregeneration, aging reversal, and organ biofabrication — enabling the transition from laboratory research to therapeutic solutions.
Leadership
and Scientific Team.
Our company is guided by globally recognized pioneers in regenerative medicine and bioprinting, whose collective expertise spans over four decades, 400+ scientific publications, and 90+ biomedical patents.

  • Dr. Alexey V. Kovalev

    Chief Scientific Officer – Regenerative Medicine & Cellular Technologies


    Leading expert in cellular regeneration and in vivo bioreactor systems, with over 25 years of biomedical research experience. His work bridges fundamental science and clinical translation in tissue engineering.


    Key facts:

    • 48 registered patents

    • 150+ peer-reviewed publications in Tissue Engineering, ACS Omega, and IJMS

    • Professor, Russian Academy of Natural Sciences

    • Senior researcher at the National Center for Traumatology and Orthopedics (Russia)

    • Leader of three officially recognized scientific directions

  • Dr. Vladimir A. Mironov

    Scientific Advisor – Bioprinting & Organ Biofabrication

    Founding figure in the global field of 3D bioprinting, combining academic depth with breakthrough achievements in organ biofabrication. His work helped shape modern bioprinting technologies and advance them from concept to application, including robotic bioprinters and the world’s first bioprinted thyroid successfully transplanted into a mouse.


    Key facts:

    • Co-author of the first scientific paper on organ printing (2003)
    • Over 200 peer-reviewed publications
    • Hirsch Index: 52
    • Scientific Director at 3D Bioprinting Solutions
    • Professor at Virginia State University (USA)
    • Developer of the first bioprinted thyroid successfully transplanted into a mouse
What We’ve Achieved.
We have translated decades of scientific research into a robust, defensible platform — moving far beyond the concept stage. Our technologies are tangible, tested, and protected.
  • Preclinical Proof-of-Concept
    • Functional spheroids tested for osteogenesis and chondrogenesis
    • Implantation feasibility demonstrated in critical-size bone defects
    • Prototype wearable bioreactor ("Regenetron") developed for fingertip regeneration
  • Granted Patents
    Nine issued Russian patents covering biocomposite spheroids, minimally invasive bone grafting methods, and personalized cellular therapy for bone and cartilage repair.
  • Engineered Medical Devices
    • In vivo bioreactor systems at lab-testing stage
    • Nutrient aerosol bioreactor architecture designed to overcome limitations of liquid media
  • Therapeutic Programs
    • Cellular treatments for neurological disorders (stroke, TBI, CP)
    • Regenerative solutions for alopecia and aging skin
    • Blueprint for a vertically integrated Biotech + Clinic model with translational focus
Scientific and Technological Foundations.
Our platform is built on foundational research in:
Cyber-physical medical devices enabling in situ tissue growth.
Very Small Embryonic-Like Stem Cells (VSELs).
Human-induced skeletal blastema cells.
Custom bioinks for orthopedic and neuro applications.
Personalized, wearable, and intraoperative bioreactor systems.
Intellectual Property Portfolio.
Selected patents span core innovations in cellular therapies, bioprinting, and minimally invasive regeneration — forming a defensible foundation for clinical translation.
  • RU 2741206
    Device for introducing a graft into a bone regenerate
  • RU 2744664
    Method for producing spheroids from periosteal cells
  • RU 2744732
    Biocomposite spheroid for bone restoration
  • RU 2744756
    Spheroid-based method for large bone defect repair
  • RU 2747087
    Method for producing biocomposite spheroids
  • RU 2748544
    Minimally invasive access for cell transplantation
  • RU 2750021
    Cellular technology for diaphysis restoration
  • RU 2757157
    Vascular autotransplantation for long bone defects
  • RU 2731314
    Cartilage spheroid production
  • Plus
    Methods for neuroregeneration, alopecia therapy, fingertip regrowth, and bioreactor design
Investment Opportunity.
Use of Funds
• Scale-up of preclinical models into pilot manufacturing
• Device certification and translational readiness acceleration
• Patent expansion in EU, US, and China
• GLP regulatory pathway initiation
• Strategic partnerships with clinical institutions
Why Invest Now
• IP-protected breakthroughs in cellular therapy and bioprinting
• Tangible validation in high-value therapeutic areas
• Platform model with recurring licensing and service revenue
• Underserved multibillion-dollar markets in aging, orthopedics, neurorepair
• Strong first-mover advantage in wearable bioreactor and in vivo printing technologies
Join us now.
We invite strategic investors to join us in shaping the future of regenerative medicine —
where living tissues are grown, restored, and personalized from the inside out.

Leave your contact details in the form below, and we will get back to you shortly.
You agree to our Terms and Conditions
© All Rights Reserved.
Made on
Tilda